Adds background in paragraphs 2,3 and FDA comment in paragraph 4
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for a regulatory action on bluebird bio's BLUE.O gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional reports of blood cancers from its use.
Skysona was approved by the FDA in 2022 for the treatment of cerebral adrenoleukodystrophy.
The therapy's prescribing information included a warning for blood cancers, including leukemia and myelodysplastic syndromes, which are a group of cancers that occur when the bone marrow produces immature blood cells instead of healthy ones.
The FDA said considering the risk of such cancers, patients should consider alternative therapies.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。